About Alzheimer's Drugs
Alzheimer's disease is a progressive and irreversible degeneration of the brain that disrupts the thinking, language, behavior, and cognitive skills of a person. It is more prevalent in people aged 65 years and above and affects more women than men. As per the Centers for Disease Control and Prevention (CDC), 5.4 million Americans are affected by this disease, and the incidence rate of disease increases with age and doubles every five years for adults beyond 65 years of age.
Technavio’s analysts forecast the global alzheimer's drugs market to grow at a CAGR of 1.90% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global alzheimer's drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Alzheimer's Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global alzheimer's drugs market: ALLERGAN, Eisai Pharmaceuticals, Johnson & Johnson, and Novartis.
Other Prominent Vendors in the market are: Amgen, and Pfizer.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is reformulation of marketed drugs. The global Alzheimer’s drugs market is currently witnessing an increasing trend of reformulation of already market drugs to increase patient adherence to the treatment. Drug delivery systems such as transdermal patches, ER formulations, and orally disintegrating tablets increase the efficacy of drugs either by increasing the patient compliance or by increasing the bioavailability of a drug.”
According to the report, one driver in the market is appropriate strategies designed to increase public awareness. Although the risk of developing Alzheimer's disease increases exponentially with age, the CDC estimates that approximately 220,000-640,000 Americans under the age of 65 years are suffering from dementia, particularly Alzheimer's disease. The early onset of symptoms of Alzheimer's disease is often called as younger-onset. However, the diagnosis of individuals with younger-onset is delayed by several months or years as these symptoms are often attributed to external factors such as head injury, improper sleep, trauma or tragedy that had occurred in the past, stress conditions, and improper diagnosis of disease.
Further, the report states that one challenge in the market is social stigma associated with Alzheimer's disease. Alzheimer's disease is perceived in different ways in different parts of the world, ranging from a component of aging to a supernatural event. This, in turn, has a negative impact on those suffering from dementia as they often refrain from reporting their symptoms to healthcare providers, leading to low diagnostic rates, thus hampering the market growth. In some parts of the world, public disclosure of such symptoms triggers negative reactions from family and friends leading to quarantine in some cases.
ALLERGAN, Eisai Pharmaceuticals, Johnson & Johnson, and Novartis.Amgen, and Pfizer.